SGS expands testing capabilities at its Glasgow facility

29 Jan 2019

Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product.

SGS has invested £7.6 million in its facility in Glasgow, UK to expand the capabilities and capacity for testing cell banks and routine bulk harvest for vaccines, gene and cell therapies, monoclonal antibodies and other recombinant protein-based biological medicines. The investment has been supported in part by a Scottish Enterprise Research and Development grant award of £1.7 million.

SGS expands testing capabilities at its Glasgow facility

The new laboratory has added an additional 1,200 m2 to the existing facility and will be adjacent to SGS’s existing global center of excellence for cell banks and viral vaccine biosafety.

The facility now totals 2,400 m2, employs 65 staff and plans to significantly increase the number of scientific and quality personnel at the site. Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product, as well as new technologies for pathogen detection, including next-generation nucleic acid sequencing and new cell-based viral detection systems. The new laboratory will also increase the capacity of all existing biosafety services and enhanced real-time polymerase chain reaction (PCR) platforms, to support viral safety and genetic stability assessment of cell banks for vaccines, gene and cell therapies.

In addition, in accordance with the requirements of the US and European Pharmacopeia, SGS will undertake the development and validation of new cell-based viral detection systems at the site.

“As the pharmaceutical industry becomes increasingly focused on large molecule biologics, vaccines, gene and cell therapies, SGS continues to increase its service capacity and capabilities in this area,” commented Archie Lovatt, Scientific Director. “This is a rapidly expanding field, where much broader and highly specialized testing expertise and equipment are required to establish and ensure the safety of novel human therapies and vaccines, and one that SGS sees as key to its strategic growth.”

Julia Brown, Director for High Value Manufacturing and Health at Scottish Enterprise, added: “This investment from SGS is testament to the strength of our life sciences sector, as well as an endorsement of the wealth of talent and skills we have to offer. This expansion is great news for Scotland, creating further high-value employment in Glasgow, as well as positioning SGS Vitrology for future growth.”

Read More

Related news

Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Onyx Scientific makes strategic investment in commercial API licence

Onyx Scientific makes strategic investment in commercial API licence

10 Jul 2019

Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

Read more 
I Holland to share the science behind tool maintenance

I Holland to share the science behind tool maintenance

9 Jul 2019

Proper maintenance - rather than replacement - of compression tooling will improve profitability.

Read more 
Catalent extends global commercial spray drying capabilities in Europe

Catalent extends global commercial spray drying capabilities in Europe

9 Jul 2019

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Read more 
Operations commence at Wasdell Group’s EU headquarters

Operations commence at Wasdell Group’s EU headquarters

8 Jul 2019

The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.

Read more 
Porvair Sciences launches first Drosophila ChIP kits

Porvair Sciences launches first Drosophila ChIP kits

4 Jul 2019

Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.

Read more 
Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

3 Jul 2019

Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

2 Jul 2019

The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids.

Read more 
Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

1 Jul 2019

Xiidra 5% is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.

Read more